🔎 Trials Near Me

Home › Ulcerative Colitis › Washington › Tacoma

Pag-aaral pangklinika para sa Ulcerative Colitis sa Tacoma, WA

14 pag-aaral para sa Ulcerative Colitis ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Tacoma (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Nagre-recruitPhase 2
  • Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07697456

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Nagre-recruitPhase 3
  • GI Alliance Tacoma, Tacoma
Edad 12 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07196748

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Nagre-recruitPhase 3
  • Washington Gastroenterology - Tacoma, Tacoma
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06937086

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Nagre-recruitPhase 2/3
  • MultiCare Health System, Tacoma
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT05076175

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Nagre-recruitPhase 2
  • Washington Gastroenterology - Tacoma, Tacoma
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07415044

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Nagre-recruitPhase 4
  • Washington Gastroenterology- GIA, Tacoma
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06095128

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Nagre-recruitPhase 3
  • Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
Lahat ng edad · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06651281

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

Nagre-recruitPhase 3
  • GI Alliance Tacoma, Tacoma
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07577856

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Nagre-recruitPhase 2
  • Site 019, Tacoma
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07012395

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Nagre-recruitPhase 2
  • Digestive Health Specialists, Tacoma
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06636656

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

Nagre-recruitPhase 3
  • MultiCare Institute for Research & Innovation, Tacoma
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06100289

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

Nagre-recruitObservasyonal na pag-aaral
  • Washington Gastroenterology, Tacoma
Edad 18 hanggang 64 · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT06398626

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Nagre-recruitPhase 3
  • Multicare Health System Institute for Research and Innovation, Tacoma
Edad 2 hanggang 17 · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT06405087

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

Nagre-recruitPhase 2
  • Mirador Therapeutics Selected Site, Tacoma
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT07113522

Pag-aaral para sa Ulcerative Colitis sa ibang lungsod

Iba pang pag-aaral sa Tacoma

Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.